These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31732842)

  • 41. The value of blood oxygenation level-dependent (BOLD) MR imaging in differentiation of renal solid mass and grading of renal cell carcinoma (RCC): analysis based on the largest cross-sectional area versus the entire whole tumour.
    Wu GY; Suo ST; Lu Q; Zhang J; Zhu WQ; Xu JR
    PLoS One; 2015; 10(4):e0123431. PubMed ID: 25875306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum and urine analysis with gold nanoparticle-assisted laser desorption/ionization mass spectrometry for renal cell carcinoma metabolic biomarkers discovery.
    Arendowski A; Ossoliński K; Ossolińska A; Ossoliński T; Nizioł J; Ruman T
    Adv Med Sci; 2021 Sep; 66(2):326-335. PubMed ID: 34273747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
    Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
    Front Oncol; 2020; 10():717. PubMed ID: 32500026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ambient ionization mass spectrometric analysis of human surgical specimens to distinguish renal cell carcinoma from healthy renal tissue.
    Alfaro CM; Jarmusch AK; Pirro V; Kerian KS; Masterson TA; Cheng L; Cooks RG
    Anal Bioanal Chem; 2016 Aug; 408(20):5407-14. PubMed ID: 27206411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
    Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
    J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney.
    Yokomizo A; Takakura M; Kanai Y; Sakuma T; Matsubara J; Honda K; Naito S; Yamada T; Ono M
    Cancer Biomark; 2011-2012; 10(3-4):175-83. PubMed ID: 22674303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot radiometabolomics integration study for the characterization of renal oncocytic neoplasia.
    Klontzas ME; Koltsakis E; Kalarakis G; Trpkov K; Papathomas T; Sun N; Walch A; Karantanas AH; Tzortzakakis A
    Sci Rep; 2023 Aug; 13(1):12594. PubMed ID: 37537362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
    Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
    J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
    Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV
    J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas.
    Falegan OS; Arnold Egloff SA; Zijlstra A; Hyndman ME; Vogel HJ
    Metabolites; 2019 Jul; 9(8):. PubMed ID: 31344778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of soluble major histocompatibility complex class I chain-related a in renal cell carcinoma patients.
    Qiu Y; Zhao YK; Yuan GJ; Zhu QG
    Asian Pac J Cancer Prev; 2013; 14(10):5651-5. PubMed ID: 24289557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
    Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
    Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
    Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
    Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
    J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolomics study of serum and urine samples reveals metabolic pathways and biomarkers associated with pelvic organ prolapse.
    Deng W; Rao J; Chen X; Li D; Zhang Z; Liu D; Liu J; Wang Y; Huang O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121882. PubMed ID: 31809960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage.
    Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Edison AS; Fernández FM
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass.
    Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MAS; Diamandis EP; Yousef GM
    Am J Pathol; 2019 Dec; 189(12):2366-2376. PubMed ID: 31761032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative Global Proteome and Lysine Succinylome Analyses Reveal the Effects of Energy Metabolism in Renal Cell Carcinoma.
    Zhang N; Gao R; Yang J; Zhu Y; Zhang Z; Xu X; Wang J; Liu X; Li Z; Li Z; Gong D; Li J; Bi J; Kong C
    Proteomics; 2018 Oct; 18(19):e1800001. PubMed ID: 29882248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.
    Zhang L; Jiang H; Xu G; Chu N; Xu N; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y; Wang L
    Biosci Trends; 2016 Jul; 10(3):210-9. PubMed ID: 27319973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.